Leidos receives new project agreement from DTRA to conduct clinical trials for Covid-19 therapeutics. Credit: fernando zhiminaicela from Pixabay.

The Defense Threat Reduction Agency (DTRA) in the US has awarded a new project agreement to Leidos to conduct clinical trials for Covid-19 therapeutics.

The cost-plus-fixed-fee agreement, which holds a $22m base value and 24 months of performance period, was awarded through the Medical CBRN Defense Consortium.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Through the new contract, Leidos plans to use a new clinical trial prototype, which uses an electronic data capture system to collect, evaluate and assess symptom severity.

This will enable real-time data collection to support rapid initiation, amendment and evaluation of clinical studies.

Leidos will use the new prototype to simultaneously conduct two clinical studies using new drug combinations for the treatment of Covid-19.

Designed to analyse the requirement of additional patients, Leidos trial prototype aims to provide quick evaluations and improvements as the study advances.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Leidos stated that these evaluations made by the new prototype could improve potential Phase III studies and also to demonstrate the efficacy using the selected drug combination.

Leidos Health Group president Liz Porter said: “This award reinforces our commitment to fighting this deadly pandemic.

“We are proud to conduct these clinical trials and support our customers’ mission to develop life-saving drugs, vaccines and therapeutics for the men and women of our armed forces.”

For this prototype project, the company will partner with Personal Health Insights, Syneos Health and SCOPE International USA.

Furthermore, Leidos noted that these clinal trials will help to pursue enhancements to military success by improving the long-term lung function and reducing neurocognitive deficits caused due to Covid-19.